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Non-competitive inhibitionClostridium perfringens is a Gram-positive spore-forming bacterium that causes food poisoning. The neur-
aminidase (NA) protein of C. perfringens plays a pivotal role in bacterial proliferation and is considered a
novel antibacterial drug target. Based on screens for novel NA inhibitors, a 95% EtOH extract of Corydalis
turtschaninovii rhizome showed NA inhibitory activity (68% at 30 lg/ml), which resulted in the isolation
of 10 isoquinoline alkaloids; namely, palmatine (1), berberine (2), coptisine (3), pseudodehydrocoryda-
line (4), jatrorrhizine (5), dehydrocorybulbine (6), pseudocoptisine (7), glaucine (8), corydaline (9) and
tetrahydrocoptisine (10). Interestingly, seven quaternary isoquinoline alkaloids 1–7 (IC50 = 12.8 ± 1.5 to
65.2 ± 4.5 lM) showed stronger NA inhibitory activity than the tertiary alkaloids 8–10. In addition, highly
active compounds 1 and 2 showed reversible non-competitive behavior based on a kinetic study. Molec-
ular docking simulations using the Autodock 4.2 software increased our understanding of receptor–
ligand binding of these compounds. In addition, we demonstrated that compounds 1 and 2 suppressed
bacterial growth.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Clostridium perfringens is a Gram-positive spore-forming bacte-
rium found in the human gastrointestinal tract, marine sediment,
insects and soil.1–3 This pathogen causes gas gangrene and food
poisoning in humans, as well as enterotoxemia and enteritis in
livestock.4,5 Food poisoning by C. perfringens in the USA and UK is
the second most common foodborne disease. In the USA, 1 million
cases of C. perfringens occur every year.6 C. perfringens secretes over
15 toxins and enzymes, including the virulence factors encoded by
the nanH, I and J genes, which can damage host tissue.7,8
Neuraminidase (EC. 3. 2. 1. 18, NA) from bacteria, named exo-a-
silidase, hydrolyzes a-glycosidic linkages of terminal sialic acid
residues in oligosaccharides, glycoproteins and glycolipids on host
cells.9,10 In fact, sialic acid, the N- or O-substituted derivatives of
neuraminic acid from monosaccharides with a nine-carbon back-
bone, plays an important role in several cell–cell interactions and
cell-molecule recognition processes and is a good source of nutri-
ents for bacteria.11,12 Bacteria can obtain sialic acid via two routes:
de novo synthesis or scavenging from the host.12–14 Neuraminidasesecreted from bacteria catalyzes the hydrolysis of the terminal sia-
lic acids of sialoglycoconjugates in diverse organisms, and free sia-
lic acid is directly transported into the bacterial membrane.14 Sialic
acid is then used as an energy and carbon source for bacterial
growth.12,14 Moreover, neuraminidase plays a key role in the initial
stages of bacterial infection, contributing to bioﬁlm formation on
glycoprotein-coated surfaces.15,16 Recent studies have highlighted
neuraminidase as a novel target for development of therapeutic
agents to treat bacterial infections.
Therefore, we aimed to develop inhibitors of bacterial NA.
Screening results of crude extracts from Corydalis turtschaninovii
rhizomes demonstrated that the 95% EtOH extract at a concentra-
tion of 30 lg/ml had a 68% inhibitory effect on NA. Moreover, the
inhibitory effects of berberine on viral NA, a quaternary isoquino-
line alkaloid, found in this plant, have been reported.17 Accordingly,
seven quaternary and three tertiary isoquinoline alkaloids from the
C. turtschaninovii rhizome were assessed for their activity against
NA in vitro. The strong inhibitors (1, and 2) were non-competitive
based on kinetic studies, and an allosteric site may have been asso-
ciated with the molecule-inhibitor interaction based on docking
simulations. Polyphenols, including ﬂavanones, isoﬂavones and
pterocarpans are known to have inhibitory activity against NA,
but the activities of alkaloids and their derivatives from natural
sources remain unknown.18–20
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2.1. Isolation and structural elucidation
Ethanol extract from C. turtschaninovii rhizome showed 68%
inhibitory activity against NA at 30 lg/ml. The ethanol extract
was subjected to column chromatography on a silica gel and
C-18 column to yield compounds 1–10. The chemical structures
of isolated compounds 1–10 were identiﬁed by comparing their
spectroscopic data (HPLC, ESI and HR-MS and 1D, 2D-NMR) with
those published previously. The compounds were identiﬁed as
palmatine (1),22,23 berberine (2),22 coptisine (3),24 pseudodehydro-
corydaline (4),22,25 jatrorrhizine (5),22 dehydrocorybulbine (6),26
pseudocoptisine (7),27 glaucine (8),28 corydaline (9),27 and tetra-
hydrocoptisine (10)29 (Fig. 1).
2.2. Enzyme inhibition activity
To evaluate antibacterial activities, the inhibition by the iso-
lated compounds of NA-catalyzed 4-methylumbelliferone forma-
tion from 4-methylumbelliferyl-a-D-N-acetyl neuraminic acid
sodium salt hydrate was evaluated using ﬂuorometeric determina-
tion with a SpectraMax M5 Multimode Reader (Molecular Devices,
USA) in triplicate. Curcumin was used as a positive control. The
results showed that palmatine (1) and berberine (2) showed strong
inhibitory activity on NA with IC50 values of 12.8 ± 1.5 and
13.5 ± 2.3 lM, respectively. Coptisine (3), pseudodehydrocoryda-
line (4), jatrorrhizine (5) dehydrocorybulbine (6), pseudocoptisine
(7), and glaucine (8) showed moderate inhibitory activity (IC50
25.1 ± 0.8 to 96.9 ± 3.2 lM). In contrast, corydaline (9) andTable 1
Neuraminidase inhibitory activities of isolated alkaloids (1–10)
Compound Bacteriad rvH1N1d,e H5N1d,f
IC50
a (lM)
1 12.8 ± 1.5 33.1 ± 2.0 29.8 ± 2.1
2 13.5 ± 2.3 38.5 ± 1.2 32.2 ± 0.5
3 25.1 ± 0.8 25.3 ± 0.4 26.4 ± 1.1
4 32.6 ± 2.1 N.Dc 83.6 ± 4.5
5 37.0 ± 1.8 66.2 ± 4.2 76.3 ± 2.1
Curcuminb 6.0 ± 2.5 10.0 ± 1.2 8.1 ± 1.5
a All compounds examined in a set of duplicated or triplicated experiment.
b Positive control.
c Not detected.
d Neuraminidase.
e Tamiﬂu (IC50: 20.5 ± 1.5 nM).
f Tamiﬂu (IC50: 88.2 ± 2.9 nM).
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Figure 1. Structures of isolated compoundtetrahydrocoptisine (10) showed little effect, with 12.7 and 4.6%,
respectively, inhibition of NA activity at 100 lM. Subsequently,
compounds 1–10 suppressed viral NA activity. Viral NAs from
rvH1N1 and H5N1 were inhibited by quaternary isoquinoline
alkaloids 1–7 (Table 1). Among them, compound 3 showed IC50
values of 25.3 ± 0.4 and 26.4 ± 1.1 lM against rvH1N1 and H5N1,
respectively, which were greater than the corresponding values
of compound 2 (38.5 ± 1.2 and 32.2 ± 0.5 lM). Compound 2 was
previously considered a viral NA inhibitor (Fig. 2).17
2.3. Enzyme kinetic study
The binding mechanisms of inhibitors were examined using
enzyme-inhibitor kinetic studies. The data for highly active com-
pounds 1 and 2 are shown in Figure 3. Plots of NA activity versus
concentration of the two inhibitors yielded a group of straight lines
passing through the origin, indicating that they were reversible
inhibitors (Fig. 3A and D). Double reciprocal Michaelis–Menten
and Dixon plots were generated by measurement of enzyme activ-
ity with various substrates at different concentrations. The results
are presented in Figure 3. These compounds showed non-compet-
itive behavior as indicated by their different Vmax values and equal
Km values in the Michaelis–Menten plot (Fig. 3B and E). Addition-
ally, the Dixon plots conﬁrmed that the Ki of compounds 1 and 2
were 16.9 ± 1.5 and 11.9 ± 1.9 lM, respectively, (Fig. 3C and F).
2.4. Structure activity relationships (SARs)
Based on their inhibition of bacterial NA, this study explored the
structure–activity relationships of isoquinoline alkaloids (1–10).Compound Bacteriad rvH1N1 H5N1d
6 41.3 ± 3.5 80.5 ± 1.8 100.2 ± 0.9
7 65.2 ± 4.5 125.7 ± 5.1 167.0 ± 1.3
8 96.9 ± 3.2 N.Dc N.Dc
9 N.Dc N.Dc N.Dc
10 N.Dc N.Dc N.Dc
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Figure 2. Effects of alkaloids (1–10) on the activity of neuraminidase from C.
perfringens (C. welchii).
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of NA than tertiary isoquinoline alkaloids (8–10). Among com-
pounds 1–7, structures with a hydroxyl group at C-3 showed low
activity against NA. For example, compounds 5 (IC50:
37.7 ± 1.8 lM) and 6 (IC50: 41.3 ± 3.5 lM), which contain a free
hydroxyl group at C-3, showed an NA inhibitory effect 3- to 3.5-fold
lower than that of compound 1 (IC50: 12.8 ± 1.5 lM). Finally,
compounds substituted with free methoxyl groups instead of 1,
3-dioxolane at C-2, 3 and C-9, 10 increased NA inhibition based
on comparisons with compounds 1 (IC50, 12.8 ± 1.5 lM), 2 (IC50,
13.5 ± 2.3 lM) and 3 (IC50, 25.5 ± 0.8 lM).Enzyme [mg/ml]
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Figure 3. (A and D) The hydrolytic activity of neuraminidase as function of enzyme co
Menten plots of neuraminidase inhibition by compounds 1 and 2. (C and F) Dixon plots2.5. Molecular simulation
Because compounds 1 and 2 exhibited strong inhibitory activi-
ties in vitro, we examined the binding mode of these compounds
with their receptor (code: 2BF6 from protein data bank) using
the docking software package AUTODOCK 4.2. Based on kinetic
studies, rigid receptor-ﬂexible ligand docking was performed to
set up grids containing the full receptor for blind testing using
the AutoDockTools. This revealed the low docking energy and allo-
steric binding site opportunities of binding forms between ﬂexible
ligands and activity sites (Fig. 4). Molecular simulation results
showed a trend similar to the enzyme assays with binding energies
for palmatine (8.66 kcal/mol) and berberine (8.27 kcal/mol).
Compound 1 was closely associated with 15 amino acids in the
receptor. Among them, GLU385, ASN386, ASN417 and ASN448
were individually linked by hydrogen bonding with 2.4, 2.3, 2.0,
and 1.9 Å distances to palmatine (1). Compound 2 was proximal
to 12 amino acids. Berberine (2) formed hydrogen bonds with
ASN417 (2.12 Å) Table 2. Interestingly, ring A of the two ligands
was close to TRY320 and HIS346 in the binding site (Fig. 4B and
Fig. 45 in supporting data). Palmatine (1) interacted only via p–p
stacking with HIS346, and berberine (2) exhibited p–p stacking
with TRY320 and HIS346. Two ligands superimposed into the
allosteric binding site are shown in Figure 4.
2.6. Antibacterial assay
To conﬁrm the antibacterial activity of compounds 1 and 2,
their effects on C. perfringens growth in the presence and absence
of the inhibitor were examined and expressed as MIC values
(Table 3). Quality control standardization of the bioassay waste [mM] Inhibitor [µM]
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Figure 4. The best binding pose of two compounds 1 (silver) and 2 (pink) into the NA. (A) Orange box is the original activity site. (B) Complex of ligand-receptor became
zoom.
Table 2
Hydrogen bonding between receptor and ligand
Ligand Receptora Distance (Å)
Palmatin GLU385 2.42
ASN386 2.33
ASN417 2.09
Berberin ASN448 1.95
ASN417 2.20
a Amino acid sequence number of receptor.
Table 3
Antibacterial activities of palmatine (1) and berberine (2)
Bacteria MIC (lM)
Palmatine (1) Berberine (2) Ampicillina
C. perfringens 44.7 ± 4.5 52.2 ± 4.7 300 ± 8.1 nM
a Positive control.
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of 300 ± 8.1 nM. Compounds 1 and 2 (which showed considerable
inhibition of bacterial NA) exhibited signiﬁcant antibacterial activ-
ity against C. perfringens, with MICs of 44.7 ± 5.5 and 52.2 ± 4.7 lM,
respectively.
3. Conclusion
We identiﬁed a novel inhibitor of NA from C. perfringens, a caus-
ative agent of food poisoning. Activity-guided fractionation of 95%
ethanol extract from C. turtschaninovii rhizome led to the isolation
of isoquinoline alkaloids 1–10. Among them, palmatine (1) and ber-
berine (2), which contain the quaternary isoquinoline alkaloid back-
bone, exhibited NA inhibitory activity. Previous reports have
examined inhibitors of two exo-sialidases for bacterial and viral
NAs because they have similar active sites and overall mechanism
of action.30,31 We also found similar results for viral and bacterial
NA. In particular, coptisine (3) showed stronger inhibitory activity
than berberine (2), which has been reported to be a viral NA inhibi-
tor.17 Isoquinoline alkaloids inhibited bacterial NA and suppressedviral activity. Based on the kinetic study andmolecular simulations,
the quaternary isoquinoline alkaloids 1 and 2 showed reversible
non-competitive behavior in the ligand-receptor interaction for
the inhibition of NA. In addition, the location for binding was pre-
dicted to be an allosteric site based on the optimal position of the
ligands. Based on this information, the negatively charged amino
acids ASN 417 and positively charged HIS 346 in the binding site,
which are common residues of amino acid for hydrogen bonds and
p–p stacking interactions with two ligands, provided little informa-
tion for the development of new non-competitive NA inhibitors.
Finally, palmatine (1) and berberine (2) suppressed bacterial growth
and may thus represent potential novel antibacterial agents.
4. Materials and methods
4.1. General experimental procedures
NMR spectra were obtained on a JNM-ECA 400 and 600 MHz
(JEOL, Tokyo, Japan) spectrometer using DMSO-d6 and methanol-
d4 as solvents. HPLC analysis using the Chemstation software was
performed using an Agilent 1200 series equipped with a binary
pump and visible wavelength detector (VWD). The analytical col-
umn was a YMC-Pack amino column (250  4.6-mm i.d.). Molecu-
lar weight was determined using ESI MS (Esquire 6000, Bruker).
Melting points were measured using an Electrothermal IA-92 00
instrument and chromatographic separations were performed by
thin-layer chromatography (TLC) with commercially available
glass plates pre-coated with normal and reverse-phase silica gel
(Merck, Darmstadt, Germany). Spots were visualized under UV
light (254 and 365 nm) and with Dragendorff reagent. Column
chromatography was performed using 230–400-mesh silica gel
(Kieselgel 60, Merck, Germany), RP-18 resins (ODS-A, 12 nm, S-
150 lm; YMC), Sephadex LH-20 (Amersham Biosciences) and the
MPLC system. Neuraminidase of Clostridium perfringens (SIGMA,
N3001), curcumin (SGIMA, C1386), p-iodonitrotetrazolium violet
(p-INT) (SIGMA I8377) and 4-methylumbellifery-a-D-N-acetylneu-
raminic acid sodium salt hydrate (SIGMA, M8639) were purchased
from Sigma–Aldrich (ST. Louis, MO, USA). rvH1N1 and H5N1 were
obtained from R&D Systems (ST. Paul, MO, USA) and Sino Biological
Inc. (Beijing, P.R. China), respectively. C. perfringens was obtained
from the Korean Culture Center of Microorganisms.
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C. turtschaninovii rhizomes were purchased from an herbal
drug-store in Jeongeup city, Jeollabuk-do, Republic of Korea, in
August 2012, and were identiﬁed by one of the authors (Prof.
Young Ho Kim). A voucher specimen (CNU-13129) was deposited
at the Herbarium of College of Pharmacy, Chungnam National
University, Republic of Korea.
4.3. Isolation and Identiﬁcation
C. turtschaninovii rhizomes (3.6 kg) were extracted with 95%
EtOH (18 L) at room temperature over 7 days. After removing sol-
vent under reduced pressure, a dark brownish residue (120 g)
was obtained. The crude extract (120 g) was separated using
silica-gel column chromatography with a gradient solvent system
of CHCl3/MeOH (20:1? 0.5:1) to yield seven fractions (1–7). Frac-
tion 1 (14 g) was subjected to MPLC using gradient elution with
CHCl3/MeOH (10:1? 2:1) to yield four sub-fractions (1.1–1.4).
Compounds 10 (20 mg) and 7 (30 mg) were isolated from fraction
1.3 (4 g) on a C-18 column eluted with H2O/MeOH (10:1? 0.1:1).
Sub-Fraction 1.4 was separated using C-18 column chromatogra-
phy with gradient elution of H2O/MeOH (10:1? 2.5:1) to afford
compound 1 (45 mg). Fraction 3 (24 g) was subjected to silica gel
column chromatography using gradient CHCl3/MeOH (20:1 ?
0.25:1) to yield seven sub-fractions (3.1–3.7). Sub-fraction 3.2
(2 g) was subjected to MPLC using gradient solvent (CHCl3/MeOH,
20:1? 0.1:1) to yield compounds 5 (13 mg) and 8 (32 mg). Sub-
fraction 3.4 (12 g) was loaded on the MPLC system and eluted with
CHCl3/MeOH (10:1? 0.5:1) to afford compounds 2 (7 mg), 4
(300 mg) and 9 (18 mg). Sub-fraction 3.6 (5 g) was chromato-
graphed using a Sephadex LH-20 column and eluted with 100%
MeOH to afford seven smaller fractions (3.6.1–3.6.7). Sub-fraction
3.6.5 (540 mg) was subjected to MPLC using gradient solvent
(CHCl3/MeOH, 20:1? 0.25:1) to yield compounds 3 (5 mg) and 6
(8 mg).
4.4. Enzyme inhibition assay
All enzyme assays were performed as described previously
using bacterial NA with minor modiﬁcations.18 Brieﬂy, each 50 ll
of NA (0.1 mg/ml) in buffer and 20 ll of the respective ligands
diluted from 100 lM to 6.25 lM dissolved in MeOH were mixed
in 96-well plates containing 80 ll of 50 mM sodium acetate buffer
(pH 5.0). Finally, 50 ll of 0.5 mM 4-methylumbelliferyl-a-D-N-
acetylneuraminic acid sodium salt hydrate were added as a sub-
strate. After starting the enzyme reaction at room temperature,
4-methylumbelliferone quantiﬁcation intensity (RFU) was mea-
sured using ﬂuorometric determination (excitation wavelength,
365 nm; emission wavelength, 450 nm) with a SpectraMax M2e
Multimode Reader (Molecular Devices, USA) for 10 min. The inhibi-
tion ratio was calculated using the equation:
Inhibitory ð%Þ ¼ 100
 ½DligandabsorbanceÞ=ðDcontrolabsorbanceÞ
 100
Curcumin was used as the positive control.
4.5. Molecular simulation
The 3D structure of the ligand was modeled using the GlycoBio-
Chem PRODRG2 server and the ﬂexible bonds of ligands were
assigned with AutoDockTools. The structure of NA (PDB ID: 2BF6)
was obtained from the protein data bank, after which the water,glycerol and O-sialic acid were removed from receptor complexes
using Chimera. All hydrogen atoms and gasteiger charges in the
receptor were added using AutoDockTools. Simulation studies
were performed using the AUTODOCK 4.2 software according to
the instructions provided on the Autodock Homepage (http://auto-
dock.scripps.edu/). Brieﬂy, to perform blind docking in AUTODOCK
4.2, the grid dimensions were establishing using grid center (X:
84.8, Y: 0.5, Z: 11.4), number of points (X: 150, Y: 200, Z: 150)
and spacing (0.375 Å). Both ligand and receptor docking were per-
formed using the Lamarckian Genetic Algorithm (Runs 50) after the
default parameter settings generated by the AutoDockTools were
used for docking, except that the maximum number of evals was
set as long. The molecular simulation results are shown in Figure 4
and were prepared using Chimera.
4.6. Antibacterial activity assay
To conﬁrm the inhibitory activity of compounds 1 and 2 on via-
ble bacteria, C. perfringenswas cultured in tryptic soy broth (TSB) at
37 C with continuous shaking in an anaerobic environment for
24 h. Growth was monitored by measuring turbidity at 600 nm.
Bacteria diluted 1:100 in TBS (198 ll) were cultured in the
presence and absence of compounds 1 and 2 dissolved in DMSO
(3.1–100 lM). A total of 40 ll of 1% p-INT was added to the each
well of the plates, followed by incubation for 30 min. Absorbance
was determined at 600 nm.21
4.7. Statistical analysis
All activity tests in the presence of inhibitors were performed in
triplicate and results are presented as the means ± standard error
of the mean (SEM). The results were subjected to analysis using
Sigma Plot (SPP Inc., Chicago, IL, USA).
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